Table 2. Antiproliferative Activities of the Compounds against a Panel of Cancer Cells with Different Status of B-Raf.
| antiproliferation
(IC50, μM) |
|||
|---|---|---|---|
| cell lines | 3o | 3s | 1 |
| Lovoa | >10 | >10 | >10 |
| SK-MEL-2a | >10 | >10 | >10 |
| NZM09a,c | >10 | >10 | 8.33 |
| NZM40a,c | 4.44 ± 1.09 | 4.35 ± 1.31 | 3.01 ± 0.31 |
| HT29b | 0.263 ± 0.02 | 0.384 ± 0.07 | 0.601 ± 0.08 |
| SK-MEL-1b | 0.202 ± 0.07 | 0.448 ± 0.07 | 1.499 ± 0.04 |
| SK-MEL-28b | 0.075 ± 0.03 | 0.257 ± 0.11 | 0.381 ± 0.15 |
| A375b | 0.046 ± 0.02 | 0.101 ± 0.05 | 0.079 ± 0.02 |
| NZM20b,c | 0.002 ± 0.001 | 0.023 ± 0.004 | 0.024 ± 0.003 |
| NZM07b,c | 0.003 ± 0.001 | 0.024 ± 0.006 | 0.036 ± 0.008 |
a
The cells harbor B-RafWT.
b
The cells express B-Raf V600E.
c
Primary cell lines derived from New Zealand metastatic melanoma patients. The IC50 values were determined using MTTa,b or sulforhodamine Bc assay. Data are mean values ± standard deviation (SD) of three independent experiments.